Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2011; 17(43): 4779-4786
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4779
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4779
Table 3 Correlation between Beclin-1 and LC3 expression with objective response rate and disease control rate in cetuximab-containing chemotherapy group and non-cetuximab-containing group in patients with advanced colorectal cancer n (%)
| Beclin-1 expression | LC3 expression | |||
| Low | High | Low | High | |
| Cetuximab-containing chemotherapy | ||||
| CR | 0 (0) | 0 (0) | 0 | 0 |
| PR | 4 (26.7) | 10 (33.3) | 9 (52.9) | 5 (17.9) |
| SD | 8 (53.3) | 7 (23.3) | 4 (23.5) | 11 (39.3) |
| PD | 3 (20.0) | 13 (43.3) | 4 (23.5) | 12 (42.8) |
| Non-cetuximab-containing chemotherapy | ||||
| CR | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PR | 9 (42.9) | 7 (36.8) | 7 (43.7) | 9 (37.5) |
| SD | 9 (42.9) | 9 (47.4) | 6 (37.5) | 12 (50.0) |
| PD | 3 (14.2) | 3 (15.8) | 3 (18.8) | 3 (12.5) |
- Citation: Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Chen XX, Wang F, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol 2011; 17(43): 4779-4786
- URL: https://www.wjgnet.com/1007-9327/full/v17/i43/4779.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i43.4779